The effect of hydrating creams on itch in psoriasis
Phase 1
- Conditions
- Psoriasis is traditionally considered a non-itchy skin disease. It seems that itch is an underestimated, and therefore undertreated aspect of psoriasis.MedDRA version: 19.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- EUCTR2017-001556-67-BE
- Lead Sponsor
- Z Brussel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Psoriasis patients
=18 years old
Any complaints of pruritus in the last week, with a VAS pruritus >5
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
Exclusion Criteria
Unable to read IC
Unable or unwilling to applicate creams according to protocol
Unwilling to stop topicals during 10 days
Recent start of systemic therapy for psoriasis (upto the investigators discretion)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Our aim is to measure the effects of (cheap) indifferent topical treatments.;Secondary Objective: To weigh the amount of used cream.;Primary end point(s): Reduction in itch (VAS-score) during and after application of Dexeryl cream (through diary). Evolution of itch after stop Dexeryl.;Timepoint(s) of evaluation of this end point: - Daily (diary)<br>- Final evaluation at day 20
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Look into a relation of itch-evolution and amount of used cream.;Timepoint(s) of evaluation of this end point: day 20